{"filing":{"accession_number":"0001193125-26-338000","cik":"0001681087","ticker":"TECX","company_name":"Tectonic Therapeutic, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"d114671d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1681087/000119312526338000/d114671d8k.htm"},"events":[{"id":25619,"run_id":23252,"accession_number":"0001193125-26-338000","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a quarterly earnings release for Q2 2026 disclosing financial results (net loss of $22.3 million, R\u0026D expenses of $18.0 million, G\u0026A expenses of $6.2 million, and cash position of $227.1 million) along with business highlights and clinical trial updates. The filing explicitly states it is furnished under Item 2.02 of Form 8-K and includes the full press release as Exhibit 99.1, which is the standard format for earnings disclosures.","company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26502,"accession_number":"0001193125-26-338000","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a quarterly earnings release for Q2 2026 disclosing financial results (net loss of $22.3 million, R\u0026D expenses of $18.0 million, G\u0026A expenses of $6.2 million, and cash position of $227.1 million) along with business highlights and clinical trial updates. The filing explicitly states it is furnished under Item 2.02 of Form 8-K and includes the full press release as Exhibit 99.1, which is the standard format for earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:17:39.213275+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26502,"accession_number":"0001193125-26-338000","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a quarterly earnings release for Q2 2026 disclosing financial results (net loss of $22.3 million, R\u0026D expenses of $18.0 million, G\u0026A expenses of $6.2 million, and cash position of $227.1 million) along with business highlights and clinical trial updates. The filing explicitly states it is furnished under Item 2.02 of Form 8-K and includes the full press release as Exhibit 99.1, which is the standard format for earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:17:39.213275+00:00","company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","filing_date":"2026-08-06"}]}